Recent Updates
Recently added Catalysts

DEB025

Phase 1

Hepatitis C Virus | Small molecule | Infectious Disease |Enanta Pharmaceuticals, Inc.|Last Updated: Jan 9, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment42
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02173574Two-way Interaction Between Alisporivir and EDP239PHASE1 COMPLETED 42Aug 1, 2014Nov 1, 2014Jan 9, 20151 Germany
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Area Under the Plasma Concentration-time Curve (AUC)
EDP239 P1: D7/15/21: 0 (pre), and postdose 1,2,3,4,5,6,8,12hr P2: at D10 pre and postdose at 1,2,3,4,5,6,8,12hr,D11/12/13/14. DEB025 P1: D15/21 at pre and postdose at 1,2,3,4,5,6,8,12hr P2: D3/10(Per2) at pre, 0.5,1,2,4,6,8,12,24,3,48,72,96,120,144,168

The following PK parameters were determined from the plasma concentration time profile of EDP239 and DEB025 using a non-compartmental method: AUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval AUC0-24: Area under the plasma concentration-time curve from time zero to 24 hours AUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration. AUClast was calculated as the sum of linear trapezoids using non-compartmental analysis. AUCinf: Area under the plasma concentration-time curve from time zero to infinity. AUCinf was calculated by adding AUClast and the value obtained from dividing the last measurable plasma concentration by λz, where λz was determined from automated linear regression of the last three time points with non-zero concentrations in the terminal phase of the log-transformed concentration-time profile

Adverse Events
Part 1: Screening (Day -22 to -2) to Day 35 Part 2: Period 1- Screening (Day -22 to -2) to Day 8 Period 2- Day -1 to 28

AEs are reviewed on an ongoing basis

Safety Labs
Part 1: Screening (Day -22 to -2), -1, 1, 7, 14, 21 Part 2: Period 1- Screening (Day -22 to -2), Day -1, 8 Period 2- Day -1, 1, 14, 28

Laboratory samples will be assessed for the following: hematology, blood chemistry, and urinalysis

Plasma Pharmacokinetics (PK) of DEB025 and EDP239: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax, ss)
EDP239 P1: D7/15/21: 0 (pre), and postdose 1,2,3,4,5,6,8,12hr P2: at D10 pre and postdose at 1,2,3,4,5,6,8,12hr,D11/12/13/14. DEB025 P1: D15/21 at pre and postdose at 1,2,3,4,5,6,8,12hr P2: D3/10(Per2) at pre, 0.5,1,2,4,6,8,12,24,3,48,72,96,120,144,168

Cmax,ss was directly determined from the raw plasma concentration-time data.

Vital Signs
Part 1: Screening (Day -22 to -2) to Day 35 Part 2: Period 1- Screening (Day -22 to -2) to Day 8 Period 2- Day -1 to 28

Blood pressure and pulse rate will be assessed for safety.

Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Open-Label Single Arm CohortEXPERIMENTAL -
Interventions
NameTypeDescription
DEB025DRUG -
EDP239DRUG -
Unlock Study Design Details
Eligibility Criteria
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male or female subjects 18 to 55 years of age * Body weight at least 50 kg Exclusion Criteria: * Women of child bearing potential * Tobacco use * History or evidence of any inherited bilirubin disease or disorder, including not not necessarily limited to Dubin-Johnson Syndro...

Countries:Germany
Unlock Eligibility Criteria